RecruitingNCT06079424

Risk Markers of Arterial Aging. The Paris Prospective Study III-2

Risk Markers of Arterial Aging and Subsequent Risk of Cardiovascular Diseases and Beyond. The Paris Prospective Study III-2


Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Enrollment

7,500 participants

Start Date

Jun 20, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.


Eligibility

Min Age: 60 YearsMax Age: 95 Years

Inclusion Criteria1

  • Being enrolled in PPS3 and having signed an informed consent for PPS3-2

Exclusion Criteria3

  • Institutionalized participants
  • Participants under guardianship
  • Participants under judicial safeguard measure

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERhigh-precision carotid echo-tracking

evaluation of vascular aging parameters and baroreflex sensitivity


Locations(1)

Centre d'Investigation Précliniques

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06079424


Related Trials